Abstract 1792
Background
Prostate cancer (PC) is the second most common type of cancer among men. During radiotherapy (RT), some of the healthy tissues can be irradiated and side effects such as urinary (UI) and fecal incontinence (FI) may occur.
Methods
This non-randomized study was conducted to determine the effect of Kegel exercises on prevention of UI and FI in PC patients undergoing RT at the Gazi Hospital in the dates of 10.12.2016-03.01.2018. 60 patients were included in the study, 30 in the experimental and 30 in the control group. Data was collected with information form, CTCAE, EORTC QLQ-C30, REALM, weekly exercise follow-up schedule. The experimental group was provided individual training on Kegel exercises, training booklet was given, and patients were followed up weekly. Data collection forms were repeated before training, at the end of the first month and second month. No similar intervention was provided for the control group. Chi-square, Mann-Whitney U, Kruskal-Wallis, Friedman, Wilcoxon tests, variance analysis were used for the data analysis.
Results
Experimental and control groups were found to have been distributed homogeneously. At the end of first month, 10% of the experimental group and 13.3% of the control group had first grade UI. At the end of second month, only 1% of the control group had first grade UI, 3.3% of the experimental group and 6,7% of the control group had second grade UI. Besides, FI was not developed in both groups. It was found that social function of the EORTC QLQ-C30 increased in the experimental group. Additionally, diarrhea, insomnia, loss of appetite in the symptom sub-scale decreased in the same group. Improvement was observed in the overall health condition of the experimental group, whereas the control group was observed to be worse (p < 0,05).
Conclusions
Although Kegel exercises were not found effective, UI rate was lower in the experimental group. It has been recommended that Kegel exercises should be performed in larger groups with long-term observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydan Eda Urvaylıoğlu, Sevinç Kutlutürkan, Diclehan Kılıç.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract